ESPR Esperion Therapeutics Inc.

56.67
+3.50  (7%)
Previous Close 53.16
Open 53.66
Price To book 5.34
Market Cap 1484495447
Shares 26,197,749
Volume 492,001
Short Ratio 8.26
Av. Daily Volume 490,082

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171183795
  2. 8-K - Current report 171181206
  3. 8-K - Current report 171180066
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 171042824
  5. 8-K - Current report 171021511

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
Bempedoic Acid - 1002-039
Hypercholesterolemia
Phase 3 initiation announced November 6, 2017. Data due 4Q 2018.
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Hypercholesterolemia
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due 2Q and 3Q 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension

Latest News

  1. Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
  2. Earnings Review and Free Research Report: Vertex’s Revenue Soared 40%; Adjusted EPS Rocketed 212%
  3. Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
  4. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
  5. Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
  6. Esperion to Host Analyst and Investor Day Event on October 17
  7. Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
  8. Cramer Remix: Here's how North Korea's missile could impa...
  9. Cramer Remix: Here's how North Korea's missile could impact the stock market
  10. These Stocks Have Quadrupled Since Last Year
  11. Edited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT
  12. The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
  13. Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
  14. Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals
  15. Esperion Therapeutics reports 2Q loss
  16. Here's What's Pushing Up Esperion Therapeutics Inc. Today

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171183795
  2. 8-K - Current report 171181206
  3. 8-K - Current report 171180066
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 171042824
  5. 8-K - Current report 171021511
  6. 424B5 - Prospectus [Rule 424(b)(5)] 171021448
  7. 424B5 - Prospectus [Rule 424(b)(5)] 171015338
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014647
  9. 8-K - Current report 171013318
  10. 8-K - Current report 171013317